These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 12114872)

  • 1. Circulating tumor markers and nuclear medicine imaging modalities: breast, prostate and ovarian cancer.
    Ugrinska A; Bombardieri E; Stokkel MP; Crippa F; Pauwels EK
    Q J Nucl Med; 2002 Jun; 46(2):88-104. PubMed ID: 12114872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Combined role of tumor markers and 18fluoro-deoxyglucose-positron emission tomography (18FDG-PET) in follow-up of cancer patients].
    Lamy PJ; Comte F; Eberlé MC
    Bull Cancer; 2005 Oct; 92(10):858-64. PubMed ID: 16266869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early diagnosis of recurrent breast cancer with FDG-PET in patients with progressive elevation of serum tumor markers.
    Suárez M; Pérez-Castejón MJ; Jiménez A; Domper M; Ruiz G; Montz R; Carreras JL
    Q J Nucl Med; 2002 Jun; 46(2):113-21. PubMed ID: 12114874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers.
    Sturgeon CM; Duffy MJ; Stenman UH; Lilja H; Brünner N; Chan DW; Babaian R; Bast RC; Dowell B; Esteva FJ; Haglund C; Harbeck N; Hayes DF; Holten-Andersen M; Klee GG; Lamerz R; Looijenga LH; Molina R; Nielsen HJ; Rittenhouse H; Semjonow A; Shih IeM; Sibley P; Sölétormos G; Stephan C; Sokoll L; Hoffman BR; Diamandis EP;
    Clin Chem; 2008 Dec; 54(12):e11-79. PubMed ID: 19042984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [1959-1999: from serum markers to 18-FDG in oncology. The experience of the René-Huguenin Center].
    Pecking AP; Mechelany-Corone C; Pichon MF
    Pathol Biol (Paris); 2000 Nov; 48(9):819-24. PubMed ID: 11141917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Nuclear Medicine in diagnosis of breast cancer].
    Iakovou IP; Giannoula E
    Hell J Nucl Med; 2014; 17(3):221-7. PubMed ID: 25397630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
    Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
    Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Position of nuclear medicine modalities in the diagnostic work-up of breast cancer.
    Buscombe JR; Holloway B; Roche N; Bombardieri E
    Q J Nucl Med Mol Imaging; 2004 Jun; 48(2):109-18. PubMed ID: 15243412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy- D-glucose.
    Torizuka T; Nobezawa S; Kanno T; Futatsubashi M; Yoshikawa E; Okada H; Takekuma M; Maeda M; Ouchi Y
    Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):797-803. PubMed ID: 12029554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of common seric tumor markers in patients with solid cancers.
    Gara S; Boussen H; Ghanem A; Guemira F
    Tunis Med; 2008 Jun; 86(6):579-83. PubMed ID: 19216452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum tumor markers.
    Perkins GL; Slater ED; Sanders GK; Prichard JG
    Am Fam Physician; 2003 Sep; 68(6):1075-82. PubMed ID: 14524394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging.
    Gallowitsch HJ; Kresnik E; Gasser J; Kumnig G; Igerc I; Mikosch P; Lind P
    Invest Radiol; 2003 May; 38(5):250-6. PubMed ID: 12750613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical value of 18F-FDG PET-CT in detecting primary tumor for patients with carcinoma of unknown primary.
    Han A; Xue J; Hu M; Zheng J; Wang X
    Cancer Epidemiol; 2012 Oct; 36(5):470-5. PubMed ID: 22504050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The influence of CA 125 and CEA levels on the results of (18)F-deoxyglucose positron emission tomography in suspected recurrence of epithelial ovarian cancer.
    Menzel C; Döbert N; Hamscho N; Zaplatnikov K; Vasvatekis S; Matic V; Wördehoff N; Grünwald F
    Strahlenther Onkol; 2004 Aug; 180(8):497-501. PubMed ID: 15292970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PET-imaging in tumors of the reproductive trac.
    Reinhardt MJ; Matthies A; Biersack HJ
    Q J Nucl Med; 2002 Jun; 46(2):105-12. PubMed ID: 12114873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Usefulness of bone gammagraphy versus tumor markers (PSA/PAP) in monitoring cancer of the prostate].
    Morote J; de Torres JA
    Actas Urol Esp; 1990; 14(4):268-70. PubMed ID: 1702258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New cancer markers.
    Duffy MJ
    Ann Clin Biochem; 1989 Sep; 26 ( Pt 5)():379-87. PubMed ID: 2683969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanoparticle-aided glycovariant assays to bridge biomarker performance and ctDNA results.
    Gidwani K; Kekki H; Terävä J; Soukka T; Sundfeldt K; Pettersson K
    Mol Aspects Med; 2020 Apr; 72():100831. PubMed ID: 31787337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of CA125, physical and radiological findings in follow-up of ovarian cancer patients.
    Fehm T; Heller F; Krämer S; Jäger W; Gebauer G
    Anticancer Res; 2005; 25(3A):1551-4. PubMed ID: 16033059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of fluorodeoxyglucose, 18F-dihydroxyphenylalanine, 18F-choline, and 18F-fluoride in bone imaging with emphasis on prostate and breast.
    Langsteger W; Heinisch M; Fogelman I
    Semin Nucl Med; 2006 Jan; 36(1):73-92. PubMed ID: 16356797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.